Clinical study of combined treatment with creatine phosphate sodium for myocardial protection in endoscopic heart surgery

doi:10.3760/cma.j.issn.1007-1245.2024.10.014

Abstract

Abstract:

Objective　To observe the effect of combined treatment of creatine phosphate sodium (CP) on myocardial ischemia and reperfusion injury in patients undergoing endoscopic heart surgery. Methods　A total of 36 patients who planned to undergo endoscopic heart surgery under cardiopulmonary bypass in the Second People's Hospital of Foshan and Affiliated Overseas Chinese Hospital of Jinan University from January 2022 to April 2023 were divided into a pre-treatment group, a post-treatment group, and a combined treatment group by the random number table method, with 12 case in each group. In the pre-treatment group, there were 8 males and 4 females, aged (58.33±12.35) years, cardiac function classification: grade III in 8 cases and grade IV in 4 cases. In the post-treatment group, there were 5 males and 7 females, aged (59.67±13.77) years, cardiac function classification: grade III in 7 cases and grade IV in 5 cases. In the combined treatment group, there were 7 males and 5 females, aged (59.92±11.29) years, cardiac function classification: grade III in 9 cases and grade IV in 3 cases. The patients underwent endoscopic mitral valve anaplasty or replacement under general anesthesia and cardiopulmonary bypass. In the pre-treatment group, 2.0 g of CP was injected intravenously before cardiopulmonary bypass, and 2.0 g of CP was added into the cardiopulmonary bypass solution. In the post-treatment group, 2.0 g of CP was injected into the cardiopulmonary bypass machine 5 min after aortic cross clamp release, and 2.0 g of CP was injected into the cardiopulmonary bypass machine before cease of cardiopulmonary bypass. In the combined treatment group, 1.0 g of CP was injected intravenously before cardiopulmonary bypass, 1.0 g of CP was added into the cardiopulmonary bypass solution, 1.0 g of CP was injected into the cardiopulmonary bypass machine 5 min after aortic cross clamp release, and 1.0 g of CP was injected into the cardiopulmonary bypass machine before cease of cardiopulmonary bypass. The time of cardiopulmonary bypass, time of aortic cross clamp, time of cardiopulmonary bypass assistance, automatic cardiac beat recovery, and postoperative use of dopamine and epinephrine were compared among the three groups. The levels of blood creatine kinase isoenzyme (CK-MB), cardiac troponin I (cTnI), and brain natriuretic peptide (BNP) were compared among the three groups before surgery, at the end of surgery, and 1 d and 2 d after surgery. F test, LSD test, χ² test, Fisher exact probability method, and rank sum test were used. Results　The proportion of epinephrine use within 48 h after surgery in the combined treatment group (1/12) was lower than that in the pre-treatment group (6/12) and post-treatment group (5/12), with a statistically significant difference (P<0.05). At the end of surgery, the level of CK-MB in the combined treatment group [(12.14±4.98) U/L] was lower than that in the pre-treatment group [(17.51±5.14) U/L], with a statistically significant difference (P<0.05). One d and 2 d after surgery, the levels of CK-MB in the combined treatment group [(27.17±11.25) U/L and (17.10±8.27) U/L] were lower than those in the pre-treatment group [(37.58±11.15) U/L and (26.46±8.98) U/L] and post-treatment group [(39.54±14.27) U/L and (24.28±7.07) U/L], with statistically significant differences (all P<0.05). At the end of surgery, the level of cTnI in the combined treatment group [(4.65±1.07) μg/L] was lower than that in the pre-treatment group [(5.86±0.99) μg/L], with a statistically significant difference (P<0.05). One d and 2 d after surgery, the levels of cTnI in the combined treatment group [(6.54±0.86) μg/L and (6.24±1.10) μg/L] were lower than those in the pre-treatment group [(8.02±1.04) μg/L and (7.22±1.07) μg/L] and post-treatment group [(9.01±0.87) μg/L and (7.45±1.08) μg/L], with statistically significant differences (all P<0.05). The BNP level of the combined treatment group [(168.64±20.19) ng/L] was lower than that of the pre-treatment group [(185.65±25.13) ng/L] 1 d after surgery, with a statistically significant difference (P<0.05). The BNP level of the combined treatment group [(134.77±22.14) ng/L] was lower than that of the pre-treatment group [(169.33±26.07) ng/L] and post-treatment group [(157.10±28.16) ng/L] 2 d after surgery, with statistically significant differences (both P<0.05). Conclusion　The combined treatment with CP is more effective on reducing myocardial ischemia and reperfusion injury during endoscopic heart surgery when compared to pre-treatment or post-treatment with CP.

Key words:

Myocardial ischemia and reperfusion injury, Creatine phosphate sodium, Pre-treatment, Post-treatment, Combined treatment, , Endoscopic heart surgery

摘要：

目的　探讨磷酸肌酸钠（CP）联合处理对腔镜下心内直视手术患者的心肌缺血再灌注（I/R）损伤的影响。方法　选择2022年1月至2023年4月在佛山市第二人民医院和暨南大学附属华侨医院就诊并计划在体外循环下行腔镜二尖瓣置换术或整形术的患者36例，采用随机数字表法，将患者分为预处理组、后处理组和联合处理组，每组12例。预处理组男8例，女4例；年龄（58.33±12.35）岁；心功能分级：Ⅲ级8例，Ⅳ级4例。后处理组男5例，女7例；年龄（59.67±13.77）岁；心功能分级：Ⅲ级7例，Ⅳ级5例。联合处理组男7例，女5例；年龄（59.92±11.29）岁；心功能分级：Ⅲ级9例，Ⅳ级3例。患者在全身麻醉和体外循环下行腔镜二尖瓣整形术或置换术。预处理组：体外循环开始前静脉注射CP 2.0 g，停搏液中加入CP 2.0 g；后处理组：主动脉开放后5 min体外循环机内注入CP 2.0 g，体外循环停止前体外循环机内注入CP 2.0 g；联合处理组：体外循环开始前静脉注射CP 1.0 g，停搏液中加入CP 1.0 g，主动脉开放后5 min体外循环机内注入CP 1.0 g，体外循环停止前体外循环机内注入CP 1.0 g。比较3组患者体外循环时间、主动脉阻断时间、体外循环辅助时间、心脏自动复跳情况以及术后多巴胺和肾上腺素的使用情况；比较3组患者术前、术毕、术后1 d和术后2 d的血肌酸激酶同工酶（CK-MB）、心肌肌钙蛋白I（cTnI）以及脑利钠肽（BNP）水平。采用F检验、LSD检验、χ²检验、Fisher确切概率法、秩和检验。结果　联合处理组术后48 h肾上腺素的使用比例（1/12）少于预处理组（6/12）和后处理组（5/12），差异有统计学意义（P<0.05）。联合处理组术毕的CK-MB水平［（12.14±4.98）U/L］低于预处理组［（17.51±5.14）U/L］，差异有统计学意义（P<0.05）；联合处理组术后1 d、术后2 d的CK-MB水平［（27.17±11.25）U/L、（17.10±8.27）U/L］均低于预处理组［（37.58±11.15）U/L、（26.46±8.98）U/L］和后处理组［（39.54±14.27）U/L、（24.28±7.07）U/L］，差异均有统计学意义（均P<0.05）。联合处理组术毕的cTnI水平［（4.65±1.07）μg/L］低于预处理组［（5.86±0.99）μg/L］，差异有统计学意义（P<0.05）；联合处理组术后1 d、术后2 d的cTnI水平［（6.54±0.86）μg/L、（6.24±1.10）μg/L］均低于预处理组［（8.02±1.04）μg/L、（7.22±1.07）μg/L］和后处理组［（9.01±0.87）μg/L、（7.45±1.08）μg/L］，差异均有统计学意义（均P<0.05）。联合处理组术后1 d的BNP水平［（168.64±20.19）ng/L］低于预处理组［（185.65±25.13）ng/L］，差异有统计学意义（P<0.05）；联合处理组术后2 d的BNP水平［（134.77±22.14）ng/L］均低于预处理组［（169.33±26.07）ng/L］和后处理组［（157.10±28.16）ng/L］，差异均有统计学意义（均P<0.05）。结论　与CP预处理或后处理比较，CP联合处理更能有效地减轻腔镜下心内直视手术心肌I/R损伤，改善心功能。

关键词:

心肌缺血再灌注损伤, 磷酸肌酸钠, 预处理, 后处理, 联合处理, 腔镜心脏手术

Wu Liling, Zhang Wu, Li Yixia, Yang Kai, Liang Jielian, Du Chuchuan, Wen Xianjie, Hu Xudong, Zhong Zhiwen.

Clinical study of combined treatment with creatine phosphate sodium for myocardial protection in endoscopic heart surgery [J]. International Medicine and Health Guidance News, 2024, 30(10): 1652-1658.

吴丽灵张武李贻霞杨凯梁结连杜楚川文先杰胡旭东钟执文.

磷酸肌酸钠联合处理用于腔镜下心内直视手术心肌保护的临床研究 [J]. 国际医药卫生导报, 2024, 30(10): 1652-1658.

References

[1] Unger P, Lancellotti P, Amzulescu M, et al. Pathophysiology and management of combined aortic and mitral regurgitation[J]. Arch Cardiovasc Dis, 2019, 112(6-7):430-440. DOI: 10.1016/j.acvd.2019.04.003.
[2] Torregroza C, Roth S, Feige K, et al. Perioperative cardioprotection - from bench to bedside: current experimental evidence and possible reasons for the limited translation into the clinical setting[J]. Anaesthesist, 2021, 70(5):401-412. DOI: 10.1007/s00101-020-00912-5.
[3] Santacruz L, Arciniegas AJL, Darrabie M, et al. Hypoxia decreases creatine uptake in cardiomyocytes, while creatine supplementation enhances HIF activation[J]. Physiol Rep, 2017, 5(16):e13382. DOI: 10.14814/phy2.13382.
[4] 胡强,姚伟,于坤,等.磷酸肌酸钠对重症心脏瓣膜手术患者心肌保护作用的临床研究[J].中国分子心脏病学杂志,2020,20(3):3400-3402.DOI:10.16563/j.cnki.1671-6272. 2020.06.012.
[5] 敖虎山,苏建林,李长营.大剂量磷酸肌酸钠预先给药对心脏瓣膜置换术患者心肌缺血再灌注损伤的影响[J].中华麻醉学杂志,2010,30(3):344-346.DOI:10.3760/cma.j.issn.0254-1416.2010.03.028.
[6] 胡旭东,罗涛,张武,等.磷酸肌酸钠对瓣膜置换术患者心肌缺血再灌注损伤的治疗作用[J].重庆医学,2012,41(1):25-27.DOI:10.3969/j.issn.1671-8348.2012.01.009.
[7] Hauge SW, Dalen H, Estensen ME, et al. Short-term outcome after open-heart surgery for severe chronic rheumatic heart disease in a low-income country, with comparison with an historical control group: an observational study[J]. Open Heart, 2021, 8(2):e001706. DOI: 10.1136/openhrt-2021-001706.
[8] Harky A, Chaplin G, Chan JSK, et al. The future of open heart surgery in the era of robotic and minimal surgical interventions[J]. Heart Lung Circ, 2020, 29(1):49-61. DOI: 10.1016/j.hlc.2019.05.170.
[9] Veiga Oliveira P, Cabral D, Antunes M, et al. Postoperative atrial fibrillation - video-assisted thoracoscopic surgery versus open surgery[J]. Port J Card Thorac Vasc Surg, 2021, 28(3):33-37. DOI: 10.48729/pjctvs.192.
[10] 阿布都赛米·艾尼.全腔镜体外循环下心脏手术后机械通气时间延长(PMV)的危险因素分析[D].乌鲁木齐:新疆医科大学,2023.DOI:10.27433/d.cnki.gxyku.2023.000819.
[11] Kloka JA, Friedrichson B, Wülfroth P, et al. Microvascular leakage as therapeutic target for ischemia and reperfusion injury[J]. Cells, 2023, 12(10):1345. DOI: 10.3390/cells12101345.
[12] Jeong DS, Park PW, Sung K, et al. Determinants of late tricuspid regurgitation after aortic-mitral double valve replacement[J]. Am J Cardiol, 2017, 119(10):1643-1649. DOI: 10.1016/j.amjcard.2017.02.013.
[13] Wang J, Xue Z, Hua C, et al. Metabolomic analysis of the ameliorative effect of enhanced proline metabolism on hypoxia-induced injury in cardiomyocytes[J]. Oxid Med Cell Longev, 2020, 2020:8866946. DOI: 10.1155/2020/8866946.
[14] 张武,李贻霞,吴丽灵,等.磷酸肌酸钠对体外循环下房室间隔缺损修补术患儿心肌能量代谢和心肺功能的影响[J].国际医药卫生导报,2022,28(5):656-662.DOI:10.3760/cma.j.issn.1007-1245.2022.05.015.
[15] Qaed E, Wang J, Almoiliqy M, et al. Phosphocreatine improves cardiac dysfunction by normalizing mitochondrial respiratory function through JAK2/STAT3 signaling pathway in vivo and in vitro[J]. Oxid Med Cell Longev, 2019, 2019:6521218. DOI: 10.1155/2019/6521218.
[16] Mingxing F, Landoni G, Zangrillo A, et al. Phosphocreatine in cardiac surgery patients: a meta-analysis of randomized controlled trials[J]. J Cardiothorac Vasc Anesth, 2018, 32(2):762-770. DOI: 10.1053/j.jvca.2017.07.024.
[17] Pietropaolo A, Pierri CL, Palmieri F, et al. The switching mechanism of the mitochondrial ADP/ATP carrier explored by free-energy landscapes[J]. Biochim Biophys Acta, 2016, 1857(6):772-781. DOI: 10.1016/j.bbabio.2016.02.006.
[18] Vnučák M, Michalová R, Graňák K, et al. Potential possibility of phosphocreatine usage in internal medicine[J]. Vnitr Lek, 2019, 65(1):30-36. DOI:10.36290/vnl.2019.008.
[19] 张武,李贻霞,吴丽灵,等.磷酸肌酸钠不同时间窗口给药对心脏联合瓣膜置换术患者心肌缺血再灌注损伤的影响[J].中国体外循环杂志,2022,20(1):15-19,37.DOI:10.13498/j.cnki.chin.j.ecc.2022.01.05.
[20] Tavares JGP, Errante PR, Govato TCP, et al. Cardioprotective effect of preconditioning is more efficient than postconditioning in rats submitted to cardiac ischemia and reperfusion1[J]. Acta Cir Bras, 2018, 33(7):588-596. DOI: 10.1590/s0102-865020180070000004.
[21] Morano M, Angotti C, Tullio F, et al. Myocardial ischemia/reperfusion upregulates the transcription of the Neuregulin1 receptor ErbB3, but only postconditioning preserves protein translation: role in oxidative stress[J]. Int J Cardiol, 2017, 233:73-79. DOI: 10.1016/j.ijcard.2017.01.122.
[22] Spannbauer A, Traxler D, Lukovic D, et al. Effect of ischemic preconditioning and postconditioning on exosome-rich fraction microRNA levels, in relation with electrophysiological parameters and ventricular arrhythmia in experimental closed-chest reperfused myocardial infarction[J]. Int J Mol Sci, 2019, 20(9):2140. DOI: 10.3390/ijms20092140.
[23] Stiermaier T, Jensen JO, Rommel KP, et al. Combined intrahospital remote ischemic perconditioning and postconditioning improves clinical outcome in ST-elevation myocardial infarction[J]. Circ Res, 2019, 124(10):1482-1491. DOI: 10.1161/CIRCRESAHA.118. 314500.
[24] Huang Z, Zhong X, Irwin MG, et al. Synergy of isoflurane preconditioning and propofol postconditioning reduces myocardial reperfusion injury in patients[J]. Clin Sci (Lond), 2011, 121(2):57-69. DOI: 10.1042/CS20100435.